Cancer name Prostate Cancer
Cancer Type PRAD
Immunotherapy type Cancer Vaccine
Treatment pAdxsi?GFP?PSMA
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature CD86
Official Symbol CD86
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description On day 8, the DCs in the trans<U+2011>fection and non<U+2011>transfection groups all showed features of mature DCs (high expression of the co<U+2011>stimulatory and MHC II molecules); the expression levels of CD80, CD83, CD86 and HLA<U+2011>DR were significantly higher in the transfected DCs than in the non<U+2011>transfected DCs (P<0.05).
PMID 26783185
Title Antitumor effect of dendritic cells transfected with prostate-specific membrane antigen recombinant adenovirus on prostate cancer: An in vitro study.